Theravance has announced that a dose-ranging 7-day Phase 2b study of TD‑4208 inhalation solution, an investigational long-acting muscarinic antagonist (LAMA) for the treatment of COPD, met its primary endpoints for all six doses. TD-4208 showed a statistically significant difference compared to placebo from baseline in trough FEV1 for doses ranging from 22 µg to 700 µg.
Theravance Senior VP of Research and Early Clinical Development Mathai Mammen said, “We are very pleased with the positive results of the Phase 2b study of TD-4208 in patients with COPD. We are encouraged that we have identified doses of TD-4208 that provide clinically meaningful levels of bronchodilation, as well as lower doses that do not. Additionally, TD-4208 demonstrated a 24 hour profile consistent with a once-a-day regimen.”
Read the Theravance press release.
